Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Inv... (s supporting the fiscal year 2010 foreca...)

HOME >> MEDICINE >> NEWS

Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Investigation

Date:4/21/2009

s supporting the fiscal year 2010 forecast include the following:

*Lexapro sales projection of approximately $2.3 billion which is unchanged from $2.3 billion in fiscal 2009. The Company projects an increase in overall prescription volume for the underlying SSRI/SNRI antidepressant market as a whole of approximately 1.5% and a decrease in Lexapro's total prescription market share of approximately 1.5 share points. Also included in the projection is a price increase which was realized in January 2009.

*Namenda sales growth of approximately 12% over the $949.3 million reported in fiscal 2009.

*Bystolic sales of approximately $195.0 million as compared with $69.2 million reported in fiscal 2009.

*Savella sales of approximately $30.0 million.

*Benicar earnings decline of approximately 5% from $195.6 million reported in fiscal 2009.

*Total net revenue (includes product sales as well as the earnings contribution from Benicar, interest income and other income) of approximately $4.1 billion, representing growth of 4% from the $3.92 billion reported in fiscal 2009 and net sales growth of 6%.

*Selling, general and administrative expense of approximately $1.3 billion. This expense includes funding continued competitive levels of support behind currently promoted products, continued launch expenses for Bystolic, our beta-blocker for the treatment of hypertension that was launched in January 2008, and launch expenses to support Savella, an SNRI indicated for the management of fibromyalgia.

*Research and development spending of approximately $575.0 million in support of a significant late-stage product pipeline. This projection includes planned milestone payments of approximately $70.0 million and represents, in total, an increase of around 13% from last year's spend levels excluding initial licensing payments.

* An effec
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
2. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
3. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
4. Forest Laboratories, Inc. Announces FDA Approval of Lexapro(R) for the Treatment of Major Depressive Disorder in Adolescents
5. German Federal Patent Court Invalidates Wake Forest NPWT Patents Licensed to KCI
6. Wake Forest Baptist and Rivulet Connect New Operating Rooms with Interactive Video
7. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
8. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
9. United States Files Complaint Against Forest Laboratories for Allegedly Violating the False Claims Act
10. Old-Growth Forests Dying Off in U.S. West
11. Forest Laboratories, Inc. Reports Q309 Diluted Earnings Per Share of $0.62, Including $0.41 Per Share Charge for New Product Licensing Fees

Post Your Comments:

Forest Laboratories, Inc. Reports Fiscal Year 2009 Fourth Quarter Reported EPS of $0.31 Including $0.45 Per Share Charge Related to the Ongoing United States Attorney's Office Inv...(s supporting the fiscal year 2010 foreca...),Health